Health Services Insights · مجلد 19 · 11786329261450733-11786329261450733
Introduction: The yearly observance of Ramadan, which includes prolonged daily fasting, presents a challenging scenario for patients with chronic illnesses, with existing studies presenting inconsistent findings on its metabolic implications. Objective: This study aimed to objectively measure the immediate and sustained impacts of Ramadan fasting on monthly mean Hemoglobin A1c (HbA1c), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) in a large, real-world cohort of Saudi Arabian patients with concomitant T2DM and HTN. Methods: A retrospective longitudinal study was carried out using electronic health record (EHR) data from a Saudi multi-facility healthcare system from December 2023 to May 2024. The analysis used a segmented regression for Interrupted Time Series (ITS) to estimate changes in outcomes, with Ramadan (March 2024) serving as the intervention point. Results: = .002), indicating a rebound impact. The reduction in SBP was not sustained, as it returned to pre-Ramadan levels in the months that followed. Conclusions: In this large Saudi cohort, Ramadan fasting was linked to transitory improvements in glycemic and blood pressure control. The ensuing rebound implies that, while fasting can be metabolically advantageous, the effects do not last without ongoing intervention. These results highlight the important necessity for rigorous post-Ramadan clinical follow-up to consolidate any gains made during the fasting period. These findings position Ramadan as a novel window for metabolic reset and a potential preventive opportunity against cardiorenal metabolic syndrome progression in high-risk populations.
Ramadan fastingtype 2 diabeteshypertensionglycemic control
Frontiers in Cellular and Infection Microbiology · مجلد 16 · 1847743-1847743
Background Carbapenem-resistant Gram-negative bacilli are an increasing threat in diabetic foot ulcer (DFU) infections, limiting therapeutic options and worsening outcomes. However, data linking specific carbapenemase genes to clinical and metabolic factors remain limited. Objectives To isolate Gram-negative bacilli from deep tissue biopsies of DFUs, determine carbapenem susceptibility by minimum inhibitory concentration (MIC) testing, detect major carbapenemase genes by multiplex qPCR, and evaluate their association with glycemic control and Wagner grade. Methods This cross-sectional study included 150 patients with infected DFUs. Isolates recovered from tissue and other specimens were identified by standard microbiological methods, and carbapenem susceptibility was assessed by MIC testing. Multiplex qPCR was used to detect bla KPC, bla NDM, bla OXA-48, bla VIM, and bla IMP, and associations between resistance determinants and clinical variables were analyzed statistically. Results The mean patient age was 56.4 ± 9.8 years, with a male predominance (61.3%), and high-grade ulcers (Wagner III–V) were present in 54.7% of patients. Klebsiella pneumoniae predominated (60.0%), followed by Pseudomonas aeruginosa and Escherichia coli (each 14.7%). Resistance to meropenem and imipenem was high (77.3% and 75.3%, respectively), and carbapenemase production was detected in 84.0% of isolates. bla KPC (28.0%) and bla NDM (24.0%) were the most prevalent genes and were significantly associated with phenotypic carbapenemase production (P = 0.002 and P = 0.006, respectively). Carbapenemase producers showed significantly higher fasting glucose and HbA1c levels than non-producers (P < 0.001), with no significant association observed for Wagner grade (P = 0.570). Conclusions DFUs showed a high burden of carbapenemase-producing Gram-negative bacilli, driven mainly by bla KPC and bla NDM. Poor glycemic control was strongly associated with these resistant infections, underscoring the need for integrated metabolic management, molecular surveillance, and antimicrobial stewardship. These findings position glycemic control as a modifiable driver of antimicrobial resistance in DFUs.
Patient Preference and Adherence · مجلد Volume 20 · 1-21
Background: Medication adherence is critical for achieving optimal glycemic control and preventing diabetes-related complications. However, poor adherence remains a major barrier to effective diabetes management worldwide. Evidence regarding factors associated with medication adherence among adults with diabetes in Saudi Arabia remains limited. This study aimed to assess medication adherence among adults with diabetes and examine associations of sociodemographic, clinical, pharmacist-related, and digital health factors with adherence levels. Methods: A cross-sectional study was conducted among adults with type 1 or type 2 diabetes attending a specialized diabetes center in Jazan, Saudi Arabia, during February-March 2025. Participants were recruited using non-probability convenience sampling. Of 489 patients approached, 388 completed the questionnaire, yielding a response rate of 79.3%. Data were collected using a bilingual (Arabic/English) electronic questionnaire. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Descriptive statistics, bivariate analyses, correlation analysis, and multinomial logistic regression were performed using IBM SPSS Statistics version 27. Results: Overall, 77.1% of participants demonstrated low medication adherence, while 16.5% and 6.4% demonstrated moderate and high adherence, respectively. In the adjusted multinomial logistic regression model, higher satisfaction with the current diabetes management plan was significantly associated with greater odds of moderate adherence (OR=1.650, 95% CI: 1.212-2.245, P=0.001) and high adherence (OR=2.038, 95% CI: 1.165-3.565, P=0.013) compared with low adherence. Insulin use was associated with moderate vs low adherence (OR=2.175, 95% CI: 1.008-4.692, P=0.048), but not with high adherence. Participants who did not use mobile applications or digital health tools had higher odds of high vs low adherence than those who used such tools (OR=2.685, 95% CI: 1.007-7.154, P=0.048). Age and comorbid conditions were not significantly associated with adherence level in the adjusted model. Frequency of pharmacist consultation was significant overall (P=0.001), although individual category comparisons did not demonstrate a consistent pattern across adherence levels. Multicollinearity diagnostics indicated no problematic collinearity (VIF=1.04-1.34; tolerance ≥0.75). Conclusion: Medication adherence was predominantly low among study participants. Higher satisfaction with diabetes management was consistently associated with greater adherence, while insulin use and digital health tool use showed category-specific associations. The unexpected association between digital-tool non-use and high adherence should be interpreted cautiously and does not establish a causal effect of digital technology on adherence. Further longitudinal and prospective studies are warranted to clarify these associations and determine how structured pharmacist engagement and personalized digital-health strategies can be optimally incorporated into patient-centered diabetes care.
OBJECTIVE: The aim of this study was to investigate the relationship between perceived stress and sleep quality with glycemic blood levels in T2DM patients in Riyadh. SUBJECT AND METHODS: This cross-sectional study evaluated a total of 309 patients diagnosed with type 2 diabetes mellitus in Riyadh, Saudi Arabia. The study comprised an initial validation and Arabic translation phase involving 160 participants, followed by an analytical phase focusing on 149 adult patients. To investigate the impact of psychosocial and metabolic factors on glycemic control (hemoglobin A1c [HbA1c]), data were collected using the Pittsburgh Sleep Quality Index (PSQI) and the Perceived Stress Scale (PSS-10), alongside clinical metrics such as body mass index (BMI) and dyslipidemia extracted from medical records. A multivariable linear regression model was utilized to identify independent factors associated with glycemic regulation within the local population. RESULTS: The multivariable regression model demonstrated robust explanatory power (adjusted R2 = 0.726, p < 0.001). Traditional risk factors, specifically elevated BMI (β = 0.448, p < 0.001) and dyslipidemia (β = 0.304, p < 0.001), were significantly associated with higher HbA1c levels. Notably, poor sleep quality emerged as a significant independent factor associated with elevated HbA1c (β = 0.261, p < 0.001), whereas perceived stress did not exhibit a significant correlation. Conversely, physical activity demonstrated a significant protective effect, correlating with lower HbA1c (β = -0.271, p < 0.001). CONCLUSION: Poor sleep quality, rather than perceived psychological stress, is a primary factor independently associated with hyperglycemia in this patient cohort. These findings suggest that standard diabetes care should integrate formal sleep assessments alongside patient care management.
type 2 diabetesperceived stresssleep qualityglycemic control
Journal of the Egyptian Ophthalmological Society · مجلد 119 (2) · 165-170
Background Diabetic retinopathy (DR) is a leading cause of visual impairment and blindness worldwide. It develops as a complication of diabetes mellitus and often progresses without noticeable symptoms until vision is severely compromised. Early detection through regular screening is crucial to prevent vision loss, as timely intervention can slow disease progression. Enhancing public awareness about DR and the importance of routine ophthalmic examinations is essential for reducing its impact. Objective This study aimed to assess the level of awareness of DR among the Saudi population. Patients and methods A cross-sectional study was conducted using an online questionnaire distributed across various regions of Saudi Arabia after obtaining Institutional Review Board (IRB) approval. A total of 1000 Saudi participants aged 18 years and above were recruited using a snowball sampling method. Results Among the participants, 65.6% were females, with the largest age group between 18 and 29 years (55.5%). The central region provided the highest response rate (25%). The study revealed a high level of awareness, with 91.6% recognizing that diabetes affects the eyes and 83.5% acknowledging the need for regular screening even without symptoms. Additionally, 93.2% understood that good glycemic control can prevent DR, while 81.6% knew that DR is treatable. Furthermore, 85% were aware that the duration of diabetes influences DR development, and 83% recognized hypertension as a contributing factor. Conclusion The Saudi population demonstrates commendable awareness of DR. Continuous public health initiatives and educational campaigns are necessary to sustain and further enhance awareness, encouraging preventive practices and early detection.
Frontiers in Pharmacology · مجلد 16 · 1507009-1507009
Background: Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and clinical settings have looked into the several metabolic pathways via which metformin protects against UC. Aim: To assess efficacy of metformin as adjunctive therapy in patients with mild to moderate UC. Methods: This clinical research was double-blinded, randomized, controlled, and involved 60 patients with mild to moderate UC. The participants were randomly assigned to one of two groups (n = 30). The control group was given 1 g of mesalamine three times a day (t.i.d.) for a period of 6 months (mesalamine group). The metformin group was given 500 mg of metformin twice daily and 1 g of mesalamine t. i.d. For a period of 6 months. Patients with UC were assessed by a gastroenterologist using the disease activity index (DAI) both at the beginning of treatment and 6 months thereafter. To evaluate the drug's biological efficacy, measurements of fecal calprotectin, serum C-reactive protein (CRP), interleukin 10 (IL-10), and nitric oxide (NO) were taken both before and after treatment. Study outcomes: Decrease in DAI and change in the level of measured serum and fecal markers. Results: = 0.04) when compared to the mesalamine group. There was a significant direct correlation between DAI and calprotectin (p < 0.0001, r = 0.551), and between DAI and CRP (p < 0.0001, r = 0.794). There was a significant negative correlation between DAI and IL-10 (p = 0.0003, r = 0.371). Conclusion: Metformin may be an effective adjunct drug in management of patients with mild to moderate UC by decreasing DAI and other inflammatory markers that were involved in the pathogenesis of UC. Clinical Trial Registration: identifier NCT05553704.
Libyan Journal of Medicine · مجلد 20 (1) · 2585617-2585617
Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.
Journal of Anatomical Society of India · مجلد 74 (2) · 92-103
Background: Diabetes mellitus poses a significant health challenge worldwide. Oxidative stress, altered lipid profile, and inflammation are linked to diabetic complications. Objective: This work aimed to assess the effects of taurine (TAU) in alloxan (ALX)-induced diabetes in rats, evaluating its antihyperglycemic, antidyslipidemic, antioxidant, and anti-inflammatory effects. In addition, evaluating the effect of TAU on hepatic, renal, and cardiac complications. Materials and Methods: Fifty rats were divided into four groups, control, TAU, ALX, and ALX + TAU. At the end of the experiment, blood and tissue were collected and subjected to serum glucose, insulin, lipid profile, liver enzyme, creatinine, urea detection, oxidative-antioxidant parameters evaluation, inflammatory, anti-inflammatory cytokines detection, and histological evaluation. Results: Experimental results demonstrated that TAU effectively mitigated hyperglycemia, dyslipidemia, oxidative stress, and inflammatory conditions induced by ALX. TAU treatment improved serum glucose and insulin levels, restored lipid profiles, enhanced antioxidant enzyme activities, and reduced lipid peroxidation. In addition, TAU ameliorated hepatic and renal function alterations preserved histological architecture in the pancreas, liver, kidney, and heart tissues, and modulated inflammatory responses by diminishing the inflammatory mediators interleukin-6 (IL-6) and tumor necrosis factor-α while augmenting the anti-inflammatory mediator IL-10. Conclusions: TAU exerts a therapeutic effect on ALX-induced hepatic, renal, and cardiac diabetic complications by lowering blood glucose levels, augmenting insulin secretion, ameliorating dyslipidemia, preserving the oxidative-redox balance, and boosting antioxidant activity. TAU has also an anti-inflammatory impact.
Frontiers in Pharmacology · مجلد 15 · 1364110-1364110
Background: Pancreatitis is characterized by inflammation of the pancreas and significantly affects quality of life. Less than 5% of pancreatitis cases are drug-induced, but recent evidence suggests a substantial risk associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The aim of this study was to compare the risk of developing pancreatitis between those using GLP-1 RAs and those using sodium-glucose transport protein 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. Methods: This study was done using the FDA Adverse Event Reporting System (FAERS) database from 2019 to 2021. This database contains information from diverse submissions from healthcare providers, patients, and manufacturers. To ensure fairness and accuracy, the risk of pancreatitis associated with other hypoglycemic agents (SGLT2 inhibitors and DPP-4 inhibitors) was also investigated. Traditional and Bayesian statistical analysis methods were used to identify disproportionate statistics and included the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and information component (IC). A drug–adverse-event combination that met the criteria of all four indices was deemed a signal. Results: The analysis of 2,313 pancreatitis reports linked to hypoglycemic agents revealed a predominant association with GLP-1 RA (70.2%) compared to DPP-4 inhibitors (15%) and SGLT2 (14.7%). Most of these reports involved female patients (50.4%), and the highest incidence occurred in those over 50 years old (38.4%). Additionally, 17.7% of the reports were associated with serious events. The ROR was significant for the risk of pancreatitis when using DPP-4 (13.2, 95% confidence interval (CI) 11.84-14.70), while the ROR for GLP-1 was 9.65 (95% CI 9.17-10.16). The EBGM was highest with DPP-4 (12.25), followed by GLP-1 (8.64), while IC was highest with DPP-4 inhibitors (3.61). Liraglutide had the greatest association with pancreatitis among the GLP-1 RAs (ROR: 6.83, 95% CI 6.60-7.07). Conclusion: The findings show that pancreatitis has a strong link with DPP-4 inhibitors and GPL1 agonists, which pose a greater risk. Among the GLP-1 agonist medications, liraglutide has been found to have an association with pancreatitis.
International Journal of Pharmaceutics X · مجلد 7 · 100232-100232
Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.
vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery
International Journal of Immunopathology and Pharmacology · مجلد 38 · 3946320231220178-3946320231220178
OBJECTIVES: Crocin, the principal water-soluble active constituent of saffron, possesses numerous pharmacological activities. The present investigation examined the potential antidiabetic and antioxidant characteristics of Crocin in rats with type-2 diabetes by administering it orally and intraperitoneally (i.p.). METHODS: After 2 weeks of a high-fat diet, streptozotocin (STZ) (i.p., 40 mg/kg) was administered to male adult rats to induce type-2 diabetes mellitus. Body weight and fasting blood glucose (FBG) were measured on days zero, weeks 1, and 2. At the end of 2 weeks of drug administration in their respective groups, fasting insulin and glucose levels were estimated, and insulin resistance (HOMA-IR) was determined. Intraperitoneal glucose (IPGTT) and insulin tolerance tests (ITT) were carried out. Histopathological investigation and biochemical parameters were estimated in pancreatic tissues. RESULTS: The Crocin (100 mg/kg) treatment has significantly improved body weight, abatement of FBG, fasting insulin, and HOMA-IR. Likewise, Crocin treatment significantly improved the glucose and insulin challenges. We observed a significantly marked elevation in endogenous antioxidant enzymes in Crocin-treated groups. Similarly, Crocin treatment reversed the histopathological changes and restored the normal integrity and function of the pancreas. CONCLUSION: The overall finding indicates that intraperitoneal administration of Crocin demonstrated better control of glycemic level and body weight. Further, it has improved insulin levels in the serum and potentiated antioxidant properties.
Type 1 diabetes mellitus (T1DM) was established to be ameliorated by islet transplantation, but the shortage of the transplanted human islet tissue and the use of immunosuppressive drugs to inhibit the rejection of allogeneic grafts make this type of therapy is limited. Nowadays, therapy with stem cells is one of the most promising future treatments. This kind of therapy could have a profound impact on both replacement, as well as regenerative therapies, to improve or even cure various disorders, including diabetes mellitus. Flavonoids have also been shown to possess anti-diabetic effects. Thus, this study aims to evaluate the effectiveness of the bone marrow-derived mesenchymal stem cells (BM-MSCs) and hesperetin in the treatment of a T1DM rat model. T1DM was induced in male Wistar rats that had been starved for 16 h via intraperitoneal injection of STZ at a dose of 40 mg/kg body weight (b.wt.). After 10 days of STZ injection, the diabetic rats were allocated into four groups. The first diabetic animal group was considered a diabetic control, while the other three diabetic animal groups were treated for six weeks, respectively, with hesperetin (given orally at a dose of 20 mg/kg b.wt.), BM-MSCs (injected intravenously at a dose of 1 × 106 cells/rat/week), and their combination (hesperetin and BM-MSCs). The use of hesperetin and BM-MSCs in the treatment of STZ-induced diabetic animals significantly improved the glycemic state, serum fructosamine, insulin and C-peptide levels, liver glycogen content, glycogen phosphorylase, glucose-6-phosphatase activities, hepatic oxidative stress, and mRNA expressions of NF-κB, IL-1β, IL-10, P53, and Bcl-2 in pancreatic tissue. The study suggested the therapy with both hesperetin and BM-MSCs produced marked antihyperglycemic effects, which may be mediated via their potencies to ameliorate pancreatic islet architecture and insulin secretory response, as well as to decrease hepatic glucose output in diabetic animals. The improvement effects of hesperetin and BM-MSCs on the pancreatic islets of diabetic rats may be mediated via their antioxidant, anti-inflammatory, and antiapoptotic actions.
type 1 diabetesbone marrow-derived mesenchymal stem cellshesperetinstreptozotocin-induced diabetes
body weight) intraperitoneally. All of the nutritional and biochemical parameters were statistically analyzed. A virtual docking study was conducted. Linalool nanoemulsion results showed the highest encapsulation efficiency (86.76%), while isoamyl acetate nanoparticles showed the lowest (69.99%). According to GC-MS analysis, encapsulation did not affect the flavoring structure with particle size distributions ranging from 277.3 to 628.8 nm. Using TEM, nanoemulsion particles appeared spherical with a desired nanometric diameter size. In the oral glucose tolerance test, flavorings in oil and nanoforms had no discernible hypoglycemia effects in normal rats. The nutritional and biochemical parameters confirmed that both normal and nanoencapsulation forms demonstrated a potential anti-hyperglycemic effect, and enhanced the rat health compared to the raw flavorings. The studied flavorings and their nanocapsules seem to have the potential double effect of a flavor compound as a food palatability enhancer with a potential beneficial effect on type 2 diabetes mellitus without any health drawbacks.
Saudi Pharmaceutical Journal · مجلد 32 (1) · 101920-101920
Several studies have found that telemedicine has the potential to enhance the outcomes of patients with diabetes. This study aimed to determine the impact of telemedicine on the clinical outcomes of patients with type 2 diabetes mellitus (T2DM) in Saudi Arabia. We conducted a cross-sectional study among T2DM patients in selected primary healthcare centers in Riyadh, Saudi Arabia, from March 1, 2023, to August 20, 2023. We looked at how telemedicine affected HbA1c control, adherence, the number of diabetic complications, and polypharmacy using adjusted multivariable logistic regression models. Among the 583 patients, 140 (24.05 %) received care via telemedicine, while 442 (75.95 %) received in-person care. Patients who utilized telemedicine had significantly better glycemic control than those who received in-person care only (AOR = 5.123, 95 % CI = 3.107-8.447). Telemedicine also showed positive effects on treatment adherence (AOR = 2.552, 95 % CI = 1.6284-4.2414). Telemedicine can effectively reduce diabetic complications (AOR = 0.277, 95 % CI = 0.134-0.571). Regarding polypharmacy, patients with telemedicine use were less likely to report polypharmacy (AOR = 0.559, 95 % CI = 0.361-0.866). Telemedicine is considered one of the factors that improve HbA1c management and might increase therapeutic adherence and reduce diabetic complications and polypharmacy.
Arabian Journal of Chemistry · مجلد 16 (10) · 105170-105170
Sambucus wightiana (SW) is a 4–5-foot herbaceous stem with 5-9 leaflets and pinnatifid leaves (15-30 cm). It is used to treat stomach disorders, as an emetic for expelling poisonous substances, and as a laxative for controlling skin diseases. Phytochemical research based on ethnopharmacological knowledge is frequently regarded as an appropriate approach for discovering new agents from higher-altitude plants. Therefore, the present study focussed on identifying, collecting, and authenticating the S. wightiana and, isolating and characterizing the phytoconstituents using the DPPH method, reducing power, total flavonoid, phenolic content, anti-hyperglycemic and antioxidant capacity. Furthermore, the evaluation of antidiabetic studies of extracts/fraction and pure phytoconstituents of S. wightiana in alloxan-induced diabetic model and OGTT methods were carried out. The observed results revealed that the methanolic extract of Sambucus wightiana has significant anti-hyperglycemic and anti-oxidant activity. The methanolic extracts of S. wightiana, a dose of alloxan/SW-400 mg/Kg (111.55 ± 6.9 mg/dl) also decreased significantly the serum ALP level (p<0.05). The methanol extracts of S. wightiana showed highly significant anti-hyperglycemic activity (p<0.05). From the methanolic extracts, alloxan/SW-400 mg/Kg (89.55 ± 2.5 mg/dl) showed highly significant decrease in serum LDL level (p<0.05) in extract-treated groups, not changing the body weight substantially and methanolic extract of S. wightiana at a dose of 400 mg/Kg exhibited substantial lipid, and blood glucose levels and liver enzymes lowering capacity compared to the diabetic control group. Consequently, the prevention of hyperglycaemia by various other drugs, S. wightiana could contribute to a new formulation with significant pharmacological effects.